HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aesthetic Medicine

1,046.464

-37.694-3.48%

Number of Gainers:1

Number of Losers:10

Number of Flat:2

PE:- -

High:1,088.265

Open:1,083.353

Low:1,024.236

Close:1,084.158

Volume:76.51M

Turnover:881.54M

Market Cap:172.09B

Float Cap:129.66B

Loading ...

Sisram Medical Reports Solid Growth in 2025

THOMSON REUTERS

BRIEF-Sisram Medical Posts FY Profit Attributable $19 Million

SISRAM MED Reports Fiscal Year Results with 24.32% Drop in Net Profit

Sisram Medical Ltd - FY Profit Attributable $19 Mln

THOMSON REUTERS

Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million

Sisram Medical launches Hallura hyaluronic acid filler###

Sisram Medical Ltd - Final Dividend of HK$0.095 per Share

THOMSON REUTERS

HAOHAI BIOTEC Repurchases Shares for HK$2.41 Million

Haohai Biological Technology's 2025 Profit Falls 40%

MT Newswires Live

Musk Officially Launches Terafab Project Targeting Annual Production of 1 Terawatt Computing Power; ZIJIN MINING Reports 61.55% Net Profit Growth for 2025

Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis

Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets

Haohai BioTech SEHK 6826 One Off C¥167.7m Loss Tests Bullish Earnings Narratives

Simply Wall St.

China Medical System Wins Desidustat Approval Raising Nephrology Growth Questions

Simply Wall St.

HAOHAI BIOTEC Announces Final Dividend of RMB 0.6 Per Share

HAOHAI BIOTEC Reports 2025 Financial Results: Net Profit Attributable to Shareholders Falls 40.3% to RMB251 Million

FOSUN PHARMA Subsidiary Gains Approval for Phase I Trial of HLX18 in Solid Tumors

FOSUN PHARMA's Sodium Thiosulfate Injection Receives Regulatory Approval

Alphamab Oncology Names Former 3SBio Executive as CFO

MT Newswires Live

China Medical System Holdings SEHK 867 Margin Decline Tests Bullish Growth Narrative

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK1593/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":1046.4642,"timestamp":1774253287512,"preClose":1084.158,"halted":0,"volume":76513931,"delay":0,"changeRate":-0.034768,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-37.693726,"latestTime":"03-23 16:00:00","open":1083.3527,"high":1088.2653,"low":1024.236,"amount":881537743,"amplitude":0.059059,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"pbRate":1.56012,"peRate":23.410508,"turnoverRate":0.003742,"increases":0,"decrements":11,"flats":2,"marketCap":172094403648,"floatMarketCap":129661000256},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1088.2653,"amplitude":0.059059,"preClose":1084.158,"low":1024.236,"pbRate":"1.56012","latestPrice":1046.4642,"volume":76513931,"delay":0,"open":1083.3527,"prevYearClose":1094.978,"prevWeekClose":1084.158,"prevMonthClose":1133.252,"prevQuarterClose":1094.978,"fiveDayClose":1079.42,"twentyDayClose":1203.443,"sixtyDayClose":1159.137,"secType":"PLATE","market":"HK","turnoverRate":0.003742,"peRate":23.410508,"marketCap":172094403648,"floatMarketCap":129661000256,"timestamp":1774253287512,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":1,"down":10,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621702181","title":"Sisram Medical Reports Solid Growth in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621702181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621702181?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:54","pubTimestamp":1774277679,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nTUA9KMWRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","01696","BK1593","BK1100"],"gpt_icon":0},{"id":"2621025197","title":"BRIEF-Sisram Medical Posts FY Profit Attributable $19 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621025197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621025197?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:45","pubTimestamp":1774277144,"startTime":"0","endTime":"0","summary":"BRIEF-Sisram Medical Posts FY Profit Attributable $19 MillionMarch 23 (Reuters) - Sisram Medical Ltd 1696.HK:FY PROFIT ATTRIBUTABLE $19 MILLIONFY REVENUE US$365.3 MLNFINAL DIVIDEND OF HK$0.095 PER SHAREFurther company coverage: 1696.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","01696","BK1593","BK1585"],"gpt_icon":0},{"id":"1108612793","title":"SISRAM MED Reports Fiscal Year Results with 24.32% Drop in Net Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1108612793","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108612793?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:42","pubTimestamp":1774276933,"startTime":"0","endTime":"0","summary":"SISRAM MED (01696) announced its annual results for the year ended December 31, 2025. The group recorded revenue of $365 million, representing a 4.7% increase compared to the previous year. Profit...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1585","01696","BK1593","BK1100"],"gpt_icon":0},{"id":"2621170498","title":"Sisram Medical Ltd - FY Profit Attributable $19 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621170498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621170498?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:22","pubTimestamp":1774275760,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1585","BK1100","01696","BK1593"],"gpt_icon":0},{"id":"2621936704","title":"Sisram Medical FY2025 Injectables Revenue More Than Doubled to USD 28 million, Revenue Rose 4.7% to USD 365 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621936704","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621936704?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:22","pubTimestamp":1774275732,"startTime":"0","endTime":"0","summary":"Sisram published an annual results announcement reporting revenue of USD 365.3 million, up 4.7%.Gross profit margin was 58.9%, down 3.2 percentage points, which management attributed to geographic and product mix changes and newly established import tariffs.Profit for the year was USD 25.01 million, down 13.1%, while adjusted net profit was USD 31.0 million, up 7.9%.Revenue from injectables was USD 28.0 million, up more than doubled, driven mainly by the establishment of a direct sales office in Thailand that accelerated Profhilo’s ramp-up.The board declared a final dividend of HKD 0.095 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL4zg1Wf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1230","01696","BK1593","00656","BK1585"],"gpt_icon":0},{"id":"2621704951","title":"Sisram Medical launches Hallura hyaluronic acid filler###","url":"https://stock-news.laohu8.com/highlight/detail?id=2621704951","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621704951?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:22","pubTimestamp":1774275729,"startTime":"0","endTime":"0","summary":"Sisram reported the launch of its Alma IQ imaging platform, positioning it as part of a broader strategy to combine diagnostics with its aesthetics treatment portfolio.The company said the rollout supports its push to integrate AI-enabled tools across its product ecosystem, which could strengthen customer retention through more standardized workflows across clinics.Management also highlighted the commercialization progress of DAXXIFY in China, citing distribution volumes reaching “tens of thousands” of units as coverage expanded across multiple provinces and cities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL8RF9VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","00656","BK1593","01696","BK1230","BK1585"],"gpt_icon":0},{"id":"2621704616","title":"Sisram Medical Ltd -  Final Dividend of HK$0.095 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2621704616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621704616?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:21","pubTimestamp":1774275709,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0T9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1100","01696","BK1585","BK1593"],"gpt_icon":0},{"id":"1166664071","title":"HAOHAI BIOTEC Repurchases Shares for HK$2.41 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1166664071","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166664071?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:36","pubTimestamp":1774258587,"startTime":"0","endTime":"0","summary":"HAOHAI BIOTEC (06826) announced that on March 23, 2026, the company repurchased 107,200 shares at a total cost of approximately HK$2.41 million.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1161","06826"],"gpt_icon":0},{"id":"2621632721","title":"Haohai Biological Technology's 2025 Profit Falls 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621632721","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621632721?lang=en_us&edition=fundamental","pubTime":"2026-03-23 12:46","pubTimestamp":1774241214,"startTime":"0","endTime":"0","summary":"Shanghai Haohai Biological Technology  booked 251 million yuan in attributable profit for 2025, down 40% from 420.4 million yuan in 2024, according to a Hong Kong bourse filing Friday.Shares of the firm fell over 1% in late morning trade Monday.Earnings per share was 1.08 yuan, compared with 1.80 yuan in the prior year.Revenue fell 8.7% year on year to 2.45 billion yuan, figures showed.The company also proposed a dividend of 0.6 yuan per share.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1593","06826","BK1161"],"gpt_icon":0},{"id":"1172909581","title":"Musk Officially Launches Terafab Project Targeting Annual Production of 1 Terawatt Computing Power; ZIJIN MINING Reports 61.55% Net Profit Growth for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1172909581","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172909581?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:33","pubTimestamp":1774222403,"startTime":"0","endTime":"0","summary":"Elon Musk has officially launched the Terafab project, which aims to achieve an annual production capacity of 1 terawatt of computing power, with deployment primarily planned for space. SpaceX and...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","LU0061477393.USD","BK4581","LU2108987350.USD","BK1521","LU0348825331.USD","LU0828237940.HKD","BK1610","LU0164865239.USD","LU1064131342.USD","BK0196","LU2063271972.USD","LU0348814723.USD","IE0034235303.USD","07766","LU0234570918.USD","LU0593848301.USD","LU1861558580.USD","SG9999004220.SGD","LU2602419157.SGD","LU0588546209.SGD","LU0348827113.USD","LU1831875114.USD","LU1655091616.SGD","LU1066053197.SGD","LU2471134523.USD","601899","LU0210536198.USD","LU0820562030.AUD","LU0651946864.USD","BK4551","BK4533","LU2471134796.USD","LU1961090484.USD","LU1242518857.USD","SGXZ86797644.SGD","LU0823411888.USD","LU1720050803.USD","LU2236285917.USD","BK1544","LU2264538146.SGD","IE00B19Z8W00.USD","BK4543","TSLP","LU2326559502.SGD","LU0327786744.USD","LU1232071149.USD","LU0348766576.USD","LU0820561818.USD","BK1191","SG9999015945.SGD","UFO","LU2289578879.USD","HK0000500386.USD","SG9999002463.SGD","LU2360107168.USD","LU0287142896.SGD","LU1429558221.USD","LU1861559042.SGD","LU1778281490.HKD","TSYY","LU1242518931.SGD","LU0096374516.USD","LU0463099449.HKD","LU0651947912.USD","BK4516","LU1145028129.USD","BK0015","LU0868486357.SGD","LU1934453819.USD","LU2543165471.USD","LU1188198961.HKD","LU1504937902.USD","LU0307460666.USD","BK0188","IE00B1XK9C88.USD","LU0326950275.SGD","BK1528","BK1515","LU1224709979.USD","LU0048580855.USD","LU1328277881.USD","LU1435385759.SGD","LU1813983027.USD","BK1594","TSLT","LU0689472784.USD","LU0149721374.USD","BK4550","LU0082616367.USD","LU0823414478.USD","BK0028","LU2750360641.GBP","LU1861215975.USD","BK0183","LU1674673428.USD","LU0345780521.USD","LU0886674414.USD","LU0345769128.USD","LU0345780281.USD","LU0228659784.USD","LU1064130708.USD","LU1674673691.USD","LU2023250330.USD","IE00B19Z8X17.USD","LU2756315318.SGD","LU2580892789.USD","LU2399975544.HKD","BK0012","TSLY","LU0516423091.SGD","LU2213484517.USD","LU0082770016.USD","LU1861220033.SGD","LU1720051108.HKD","LU0964807845.USD","LU3063872942.SGD","LU1769817179.HKD","LU1997245094.SGD","LU0163747925.USD","LU0181495838.USD","SGXZ81163826.USD","TESL","LU2097828631.EUR","LU0634319403.HKD","LU0320765059.SGD","LU0266512127.USD","LU0531971595.HKD","LU1629891620.HKD","LU1794554557.SGD","LU1064131003.USD","LU2097828805.USD","LU2417539215.USD","LU0797268264.HKD","TLA","LU1551013425.SGD","BK4588","LU1366192091.USD","TSLS","LU1515016050.SGD","LU0918141887.USD","LU2039709279.SGD","LU1769817096.USD","LU0348816934.USD","LU0918141705.HKD","BK4527","LU2403377893.USD","LU2420271590.USD","HK0000306685.HKD","LU0561508036.HKD","LU2226246903.HKD","BK0242","LU0540923850.HKD","IE00BWXC8680.SGD","LU0820561909.HKD","SG9999015986.USD","TSLO","LU0620787316.HKD","BK1238","LU2250418816.HKD","TSLR","BK1198","LU0173614495.USD","SGXZ49509284.SGD","LU1997244956.HKD","LU0348735423.USD","LU0370786039.SGD","ZIJMY","02899","LU1303224171.USD","LU2097828714.EUR","LU1551013342.USD","BK4574","HK0000306701.USD","BK1505","LU1066051498.USD","HK0000320223.HKD","LU0198837287.USD","SG9999015978.USD","LU0164880469.USD","LU0719512351.SGD","TSLG","LU0821914370.USD","LU1997245177.USD","LU0431992006.USD","BK4555","LU0316494557.USD","TSLZ","LU0345770993.USD","LU0456854461.SGD","LU1481107354.HKD","TSLW","SG9999015952.SGD","LU2756315664.SGD","LU2471134952.CNY","TSLQ","LU2580892862.HKD","IE00B1BXHZ80.USD","BK1600","LU0417516738.SGD","LU0979878070.USD","LU1914381329.SGD","LU0056508442.USD","BK4598","IE00B19Z9505.USD","LU1282648689.USD","LU0516422440.USD","LU1988902786.USD","HK0000252152.HKD","HK0000320264.USD","BK1592","LU0943347566.SGD","LU0266512473.USD","LU1720051017.SGD","LU0572944931.SGD","LU2097828557.USD","TSLA","SGXZ62798434.SGD","LU1719994722.HKD","LU0737861699.HKD","LU0323591593.USD","LU1979443071.USD","LU0516422366.SGD","LU0314109678.HKD","LU2097828474.EUR","TSL","LU2213496289.HKD","LU0228367735.SGD","LU1852331112.SGD","TSLI","LU2896262040.SGD","LU0828237510.HKD","LU1051769294.HKD","LU0871576103.HKD","LU0106252389.USD","LU2148510915.USD","IE00BJLML261.HKD","LU2750360997.AUD","LU0244354667.USD","LU0077335932.USD","LU0165289439.USD","LU1066051225.USD","BK1116","LU2360106780.USD","LU0329678337.USD","BK0077","LU0345769631.USD","BK1589","LU0672654240.SGD","LU1105468828.SGD","LU0097036916.USD","LU0469268626.HKD","LU1770034418.SGD","IE00BSNM7G36.USD","BK1593","IE00BK4W5M84.HKD","TSII","LU1051768304.USD","LU0328353924.USD","LU0737861772.HKD","IE00BK4W5L77.USD","BK4511","BK0127","LU2087621335.USD","BK4534","LU0466842654.USD","LU0140636845.USD","CRSH","LU2290526834.HKD","BK4612","LU0049853897.USD","LU2462157665.USD","BK4604","BK4592","LU0708995401.HKD","LU1267930730.SGD","LU2456880835.USD","LU0109391861.USD","LU1548497426.USD","LU1048596156.SGD","LU0234572021.USD","LU2471134879.HKD","LU0039217434.USD","LU0417516902.SGD","LU0516422952.EUR","LU0345770308.USD","LU0348723411.USD","LU0348767384.USD","LU0329678170.USD","BK4585","TSDD","BK4099","TSLL","LU2357305700.SGD","LU0516423174.USD","LU2495084118.USD","IE0032431581.USD","LU0082770016.SGD","LU0043850808.USD","LU0211977185.USD","LU0053666078.USD","LU1066051811.HKD","LU1251922891.USD","LU1808992512.USD","TEST","LU0164939612.USD","HK0000252160.HKD","LU2249611893.SGD","BK4548","LU1255011170.USD","80883"],"gpt_icon":1},{"id":"2621714840","title":"Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714840","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621714840?lang=en_us&edition=fundamental","pubTime":"2026-03-22 18:08","pubTimestamp":1774174088,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completes enrollment of 500 patients in China Phase 3 trial of anaprazole sodium enteric-coated tablets for reflux esophagitis. Xuanzhu reported full enrollment of 500 adults in a China Phase 3 trial of its product Anaprazole Sodium enteric-coated tablets  for reflux esophagitis.The trial milestone positions the program for potential expansion beyond Anaprazole’s existing China approval for duodenal ulcer treatment.Completion of enrollment may support near-term differentiation in the domestic reflux esophagitis market by advancing a locally developed therapy through late-stage development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL6JMbm8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1191","02575","BK1515","BK1593"],"gpt_icon":0},{"id":"2621714823","title":"Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714823","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621714823?lang=en_us&edition=fundamental","pubTime":"2026-03-22 18:08","pubTimestamp":1774174083,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical completes enrollment of 500 subjects in China Phase III reflux esophagitis trial of anaprazole sodium tablets. Xuanzhu Biopharma reported completion of enrollment of 500 subjects in a China Phase III trial of anaprazole sodium enteric-coated tablets  for adult reflux esophagitis.The pivotal study is multi-center, randomized, double-blind, double-dummy, and active-controlled.The primary endpoint is endoscopic healing rate within 8 weeks of treatment.Secondary endpoints include endoscopic healing rate at week 4 and symptom changes at week 4 and week 8.No trial results were reported in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original conten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL8162Qw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460","BK1600","BK1515","02575","BK1593","BK1191"],"gpt_icon":0},{"id":"2621379178","title":"Haohai BioTech SEHK 6826 One Off C¥167.7m Loss Tests Bullish Earnings Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2621379178","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621379178?lang=en_us&edition=fundamental","pubTime":"2026-03-22 03:10","pubTimestamp":1774120209,"startTime":"0","endTime":"0","summary":"Shanghai Haohai Biological Technology (SEHK:6826) has wrapped up FY 2025 with fourth quarter revenue of C¥573.9 million and a basic EPS loss of C¥0.23, while the trailing twelve month basic EPS sits at C¥1.08 on revenue of about C¥2.5 billion. Over recent periods the company has seen quarterly revenue move between C¥573.9 million and C¥685.9 million, with basic EPS ranging from a loss of C¥0.23 to a profit of C¥0.52. This presents a mixed earnings picture across the year. With a trailing net...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6826/shanghai-haohai-biological-technology-shares/news/haohai-biotech-sehk-6826-one-off-c1677m-loss-tests-bullish-e","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6826/shanghai-haohai-biological-technology-shares/news/haohai-biotech-sehk-6826-one-off-c1677m-loss-tests-bullish-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BLSG","06826","BLSX","688366","BK4112","BK1593"],"gpt_icon":0},{"id":"2621758686","title":"China Medical System Wins Desidustat Approval Raising Nephrology Growth Questions","url":"https://stock-news.laohu8.com/highlight/detail?id=2621758686","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621758686?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:10","pubTimestamp":1774019418,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has received marketing approval in China for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis chronic kidney disease patients.\nThe approval adds a new drug to the company’s nephrology portfolio and targets a major unmet medical need in China.\n\nChina Medical System Holdings is drawing fresh attention after this new approval, with the share price at HK$13.49 and a 1 year return of 81.4%. The stock has also seen a 6.1% gain over...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/china-medical-system-wins-desidustat-approval-raising-nephro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/china-medical-system-wins-desidustat-approval-raising-nephro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999004220.SGD","BK1593","00867","BK1191","SG9999015978.USD","IE00BVYPNP33.GBP","LU2488822045.USD","SG9999015986.USD","IE00BVYPNQ40.USD","IE00BYV24P56.USD","IE00BMCWC346.EUR","SG9999015952.SGD","SG9999015945.SGD","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"1165235786","title":"HAOHAI BIOTEC Announces Final Dividend of RMB 0.6 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1165235786","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165235786?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:54","pubTimestamp":1774018454,"startTime":"0","endTime":"0","summary":"HAOHAI BIOTEC (06826) has declared a final dividend of RMB 0.6 per share for the fiscal year ending December 31, 2025.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1593","BK4588","VIG","06826","BK1161"],"gpt_icon":0},{"id":"1197429502","title":"HAOHAI BIOTEC Reports 2025 Financial Results: Net Profit Attributable to Shareholders Falls 40.3% to RMB251 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1197429502","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197429502?lang=en_us&edition=fundamental","pubTime":"2026-03-20 22:40","pubTimestamp":1774017625,"startTime":"0","endTime":"0","summary":"HAOHAI BIOTEC (06826) announced its annual results for the period ending December 31, 2025. The company reported revenue of RMB2.446 billion, representing a decrease of 8.7% compared to the previous...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826","BK1161","BK1593"],"gpt_icon":0},{"id":"1162468602","title":"FOSUN PHARMA Subsidiary Gains Approval for Phase I Trial of HLX18 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1162468602","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162468602?lang=en_us&edition=fundamental","pubTime":"2026-03-20 17:06","pubTimestamp":1773997610,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., along with its controlled subsidiaries (collectively \"Henlius\"), has received approval from the National...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0012","BK1593","BK0196","BK1515","BK0096","BK0175","BK1191","BK0028","BK0188","BK0239","02196","BK0183","BK0060","600196"],"gpt_icon":0},{"id":"1109630359","title":"FOSUN PHARMA's Sodium Thiosulfate Injection Receives Regulatory Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1109630359","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109630359?lang=en_us&edition=fundamental","pubTime":"2026-03-20 17:01","pubTimestamp":1773997266,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary, Chongqing Kailin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0175","BK0187","BK0096","BK1515","BK0183","BK0060","BK1593","BK0239","02196","BK0188","BK0196","600196","BK0028","BK1191"],"gpt_icon":0},{"id":"2620230200","title":"Alphamab Oncology Names Former 3SBio Executive as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2620230200","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620230200?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:32","pubTimestamp":1773833554,"startTime":"0","endTime":"0","summary":"Alphamab Oncology (HKG:9966) named Wang Fei as its chief financial officer effective March 16, according to a Wednesday Hong Kong bourse filing.Wang was the CFO of 3SBio (HKG:1530) from April 2020 to April 2023.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1593","HK0000165453.HKD","BK1161","BK1574","01530","09966"],"gpt_icon":0},{"id":"2620574258","title":"China Medical System Holdings SEHK 867 Margin Decline Tests Bullish Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2620574258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620574258?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:05","pubTimestamp":1773828329,"startTime":"0","endTime":"0","summary":"China Medical System Holdings (SEHK:867) has put fresh numbers on the table for FY 2025, posting first half revenue of C¥4.0b and basic EPS of C¥0.39, alongside trailing twelve month revenue of C¥7.9b and EPS of C¥0.68. The company has seen revenue move from C¥3.6b in the first half of FY 2024 to C¥4.0b in the first half of FY 2025 and trailing revenue shift from C¥7.5b to C¥7.9b, with basic EPS across reported halves ranging between C¥0.29 and C¥0.39. For you as an investor, the key question...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/china-medical-system-holdings-sehk-867-margin-decline-tests","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/china-medical-system-holdings-sehk-867-margin-decline-tests","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999004220.SGD","LU2488822045.USD","BK1593","00867","BK1191","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","BLSG","IE00BVYPNQ40.USD","BLSX","IE00BYV24P56.USD","SG9999015978.USD","BK4112","SG9999015986.USD","SG9999015945.SGD","IE00BMCWC346.EUR","SG9999015952.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":59,"code":"91000000","status":"200"}]}}